ScholarIQanswers from OpenAlex & ORCID
Toyoaki Hida
ResearcherPublications, citations & collaboration network
Toyoaki Hida is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Toyoaki Hida have?
ScholarIQindexed works
Toyoaki Hida has 449 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Toyoaki Hida have?
ScholarIQcitation count
Toyoaki Hida has 29,113 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Toyoaki Hida?
ScholarIQh-index
Toyoaki Hida has an h-index of 76 in OpenAlex.
What is the i10-index of Toyoaki Hida?
ScholarIQi10-index
Toyoaki Hida has an i10-index of 209 in OpenAlex.
What is the ORCID of Toyoaki Hida?
ScholarIQorcid
The ORCID for Toyoaki Hida is on the source record.
What is the OpenAlex record for Toyoaki Hida?
ScholarIQopenalex
The OpenAlex for Toyoaki Hida is on the source record.
What are the most-cited papers on Toyoaki Hida?
ScholarIQmost cited works
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara
Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer
Jürgen Wolf, Takashi Seto, Ji‐Youn Han, Noemı́ Reguart, Edward B. Garon, Harry J.M. Groen, Daniel S.W. Tan, Toyoaki Hida, Maja J.A. de Jonge, Sergey Orlov, Egbert F. Smit, Pierre-Jean Souquet, Johan Vansteenkiste, Maximilian J. Hochmair, Enriqueta Felip, Makoto Nishio, Michael Thomas, Kadoaki Ohashi, Ryo Toyozawa, Tobias R. Overbeck, Filippo de Marinis, Tae Min Kim, Eckart Laack, Anna Robeva, Sylvie Le Mouhaër, Maeve Waldron-Lynch, B. Sankaran, O. Alejandro Balbin, Xiaoming Cui, Monica Giovannini, Mikhail Akimov, Rebecca S. Heist
Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, Young Hak Kim, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka, Fumio Imamura, Katsuyuki Hotta, Satoshi Watanabe, Kōichi Goto, Miyako Satouchi, Toshiyuki Kozuki, Takehito Shukuya, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, T. Asakawa, Ryoichi Asabe, Tomohiro Tanaka, Tomohide Tamura
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
Takashi Seto, Terufumi Kato, Makoto Nishio, Kōichi Goto, Shinji Atagi, Yukio Hosomi, Noboru Yamamoto, Noboru Yamamoto, Toyoaki Hida, Makoto Maemondo, Kazuhiko Nakagawa, Seisuke Nagase, Isamu Okamoto, Takeharu Yamanaka, Kosei Tajima, Ryosuke Harada, Masahiro Fukuoka, Nobuyuki Yamamoto, Nobuyuki Yamamoto
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Glenwood Goss, Chun‐Ming Tsai, Frances A. Shepherd, Lyudmila Bazhenova, Jong Seok Lee, Gee‐Chen Chang, Lucio Crinò, Miyako Satouchi, Quincy S. Chu, Toyoaki Hida, Ji‐Youn Han, Óscar Juan, Frank Dunphy, Makoto Nishio, Jin‐Hyoung Kang, Margarita Majem, Helen Mann, Mireille Cantarini, Serban Ghiorghiu, Tetsuya Mitsudomi